Di-n-propylessigsaure
Brand names,
Di-n-propylessigsaure
Analogs
Di-n-propylessigsaure
Brand Names Mixture
Di-n-propylessigsaure
Chemical_Formula
C8H16O2
Di-n-propylessigsaure
RX_link
http://www.rxlist.com/cgi/generic2/depakene.htm
Di-n-propylessigsaure
fda sheet
Di-n-propylessigsaure
msds (material safety sheet)
Di-n-propylessigsaure
Synthesis Reference
Oberreit, Ber.29, 1998 (1896)
Di-n-propylessigsaure
Molecular Weight
144.211 g/mol
Di-n-propylessigsaure
Melting Point
120 - 130 oC
Di-n-propylessigsaure
H2O Solubility
Slightly soluble (1.3 mg/mL)
Di-n-propylessigsaure
State
Solid
Di-n-propylessigsaure
LogP
2.549
Di-n-propylessigsaure
Dosage Forms
Capsule (250 mg); Syrup (250 mg drug/5mL syrup)
Di-n-propylessigsaure
Indication
For use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
Di-n-propylessigsaure
Pharmacology
Valproic Acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.
Di-n-propylessigsaure
Absorption
Rapid absorption from gastrointestinal tract.
Di-n-propylessigsaure
side effects and Toxicity
Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.
Di-n-propylessigsaure
Patient Information
Since valproate products may produce CNS depression, especially when combined with another CNS depressant (eg, alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.
Di-n-propylessigsaure
Organisms Affected
Humans and other mammals